Community Practice Experiences with a Variety of Immunomodulatory Agents Co-Administered with Pegloticase for the Treatment of Uncontrolled Gout.

Published in: Rheumatology and therapy (2022)

These real-world findings provide further support for increased pegloticase response rates when co-treatment with immunomodulating therapy is used.

Keyphrases